Clinical experience with intravenous fenoldopam.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Fenoldopam is a novel dopaminergic agent developed as a selective dopamine-1 (DA1) receptor agonist.
• Preclinical and clinical studies indicate its potential as a potent renal and peripheral vasodilator.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous fenoldopam in patients with severe hypertension.
• To assess the effects of fenoldopam on cardiac hemodynamics in patients with moderate to severe heart failure.

Main Methods:

• Intravenous administration of fenoldopam in dose-related studies involving normal volunteers and patients with hypertension and heart failure.
• Comparison of fenoldopam's efficacy and side effect profile against sodium nitroprusside in clinical trials.

Main Results:

• Fenoldopam demonstrated dose-related decreases in blood pressure and significant increases in renal blood flow, diuresis, and natriuresis in hypertensive patients.
• In heart failure patients, fenoldopam acutely increased cardiac output and stroke volume while decreasing systemic vascular resistance.
• Fenoldopam was found to be as effective as sodium nitroprusside in treating severe hypertension and heart failure, with a potentially better side effect profile.

Conclusions:

• Intravenous fenoldopam is an efficacious agent for treating severe hypertension and acute congestive heart failure.
• Its mechanism as a DA1 agonist leads to decreased vascular resistance, diuresis, natriuresis, and improved cardiac hemodynamics.
• Fenoldopam presents a viable alternative treatment option for these cardiovascular conditions.